Syntara has completed full recruitment in its Phase 2 trial evaluating SNT-5055, in combination with ruxolitinib, treating the bone marrow cancer myelofibrosis.
- Recruitment target achieved as 15th patient dosed
- 12 patients exceed one month treatment and surpasses minimum threshold proposed in FDA discussions for safety evaluation.
- No drug related dropouts & no serious adverse reactions
- Syntara expects to announce interim data in December 2024, spurring additional regulatory discussions
Click here to read more
